Takeda Pharmaceutical Company Limited

Cornell University

Tri-Institutional Therapeutics Discovery Institute

Takeda Chemical Industries, Inc.

The Rockefeller University

Other

Memorial Sloan Kettering Cancer Center

Toshihiro Imaeda

Shinji Nakamura

Masakuni Kori

Yasutomi Asano

Eiji Honda

Rei Okamoto

Gang Herbert Lin

Tzu-Tshin Wong

Ikuo Fujimori

Kenjiro Sato

Satoshi Sasaki

Masaki Seto

Shuichi Furuya

Thomas Tuschl

Minoru Nakamura

Masashi Toyofuku

Carl F Nathan

Masaki Ogino

Taku Kamei

Jinichi Yonemori

Hideo Suzuki

Masami Yamada

Haruhi Ando

Kazuaki Takami

Tomohiro Okawa

Masataka Murakami

Hironobu Maezaki

Ayumu Sato

Makoto Kamata

Takahiro Sugimoto

Shinkichi Suzuki

Norihito Tokunaga

Yuya Oguro

Yasuyoshi Arikawa

Shoji Fukumoto

Masaki Daini

Tomoaki Hasui

Osamu Ujikawa

Michael Andrew Foley

Kazuyoshi Aso

Wenhu Zhan

Ryoma Hara

Trevor Morgan

Michiyo Mochizuki

Tomohiro Ohashi

Kenichiro Shimokawa

Shinobu Sasaki

Takeshi Wakabayashi

Takafumi Yukawa

Akinori Toita

Steve Swann

Laura Kirkman

Tomoko Ohashi

Mayako Michino

John D Ginn

Masanori Kawasaki

Daisuke Tomita

J Fraser Glickman

Yasuhiro Tsukimi

Lodoe Lama

Satoshi Mikami

Koichiro Fukuda

Jumpei Aida

Hiroshi Nara

Shinji Morimoto

Eiji Kimura

Kouichi Iwanaga

Makoto Fushimi

Fumiaki Kikuchi

Hiroshi Imoto

Dinshaw J Patel

Akira Kaieda

Tomoko Ashizawa

Ryosuke Arai

Hiroyuki Kakei

Shogo Hashizume

Sachie Takashima

Takanobu Kuroita

Michael Miller

Goushi Nishida

Takashi Miki

Fumie Yamaguchi

Chunxiang Wang

Toru Yamashita

Tri-cyclyl nitrogen-containing heterocyclic compounds are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.

Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R', R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Macrocyclic compounds as proteasome inhibitors

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R, R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, R, R, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Peptidomimetic proteasome inhibitors

1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.

Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS

Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (&#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Heterocyclic compound and use thereof

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, RR, R&#x2032;, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. 

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Nitrogen-containing heterocyclic compound

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification,or a salt thereof.

Sulfonamide derivative and use thereof

Growing community of inventors

Kanagawa, Japan

Toshihiro Imaeda